ASSOCIATION OF COMMUNITY CANCER CENTERS RELEASES FIVE ABSTRACTS AND POSTER AT ASCO ANNUAL MEETING

Abstracts assess gaps in patient awareness of NSCLC biomarker test timing, the role of a precision medicine steward, perceptions and use of RPM technology in rural cancer programs

Rockville, MD – The Association of Community Cancer Centers (ACCC) today announced the five abstracts and a poster presentation that will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2-6, 2023, in Chicago, IL.

The abstract topics span across the multidisciplinary cancer care team. Topics include differences in perceptions and use of remote patient monitoring (RPM) technology in rural cancer programs, oncology financial advocacy services guidelines, barriers and facilitators to the discussion of cancer clinical trials, the role of precision medicine steward, assessing current diagnostic, staging, and treatment practices in community and academic centers for stage IB-IIIA non-small cell lung cancer, and gaps and factors in patient awareness of biomarker test timing and purpose in NSCLC.

“We know that effective cancer care requires collaboration across the multidisciplinary team, and this year’s ACCC presentations to the oncology community capture the wide range of cancer care services that patients depend on to receive proper diagnosis and treatment,” said Olalekan Ajayi, PharmD, and President of ACCC. “From financial services to new remote patient monitoring technologies, the community must deepen our understanding of all facets of multidisciplinary cancer care to improve patient care.”

ACCC Abstracts released at ASCO Annual Meeting in June 2023:

• (Poster) Differences in Perceptions and Use of Remote Patient Monitoring Technology in Rural Cancer Programs
• Oncology Financial Advocacy Services Guidelines: Results of a Delphi study
• Innovative role of Precision Medicine steward
• Assessing current diagnostic, staging, and treatment practices in community and academic centers for individual with stage IB-IIIA non-small cell lung cancer (NSCLC)
• Barriers and Facilitators to Discussion of Cancer Clinical Trials: a Qualitative Study
• Gaps and factors in patient awareness of biomarker test timing and purpose in Non-Small Cell Lung Cancer (NSCLC): baseline assessment for implementation of 4R Oncology Model